Lisal Mueller News Today

This week in Washington IP news, as a new school year begins, the United States Patent and Trademark Office (USPTO) looks at the latest research on invention education.

Nearly 30% of biologics patent rejections result from a lack of adequate description. Rejections of this sort may rise in light of the Supreme Court’s decision in Amgen v. Sanofi. Increasingly, building strong patent applications in this complex and litigious biologics space will require more robust specifications, with solid and well-supported claims, which means applications backed by strong IP searches…

Nearly 30% of biologics patent rejections result from a lack of adequate description. Rejections of this sort may rise in light of the Supreme Court’s decision in Amgen v. Sanofi. Increasingly, building strong patent applications in this complex and litigious biologics space will require more robust specifications, with solid and well-supported claims, which means applications backed by strong IP searches…